Clinical Trial Update: Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TAS-102 (trifluridine/tipiracil) plus best supportive care vs placebo plus BSC in patients with refractory metastatic gastric cancer; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Refractory Metastatic Gastric Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-09-16